Orforglipron

Novo Nordisk Seeks FDA Approval as Eli Lilly's Weight-Loss Pill Advances

Novo Nordisk files for FDA approval of its oral anti-obesity medication, following Eli Lilly's phase III success with orforglipron, the first oral GLP-1 to achieve this milestone.